- Home
- STOK vs SVRA Comparison
STOK vs SVRA Comparison
Compare STOK & SVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STOK
- SVRA
- Stock Information
- Founded
- STOK 2014
- SVRA 2007
- Country
- STOK United States
- SVRA United States
- Employees
- STOK N/A
- SVRA N/A
- Industry
- STOK Biotechnology: Pharmaceutical Preparations
- SVRA Biotechnology: Pharmaceutical Preparations
- Sector
- STOK Health Care
- SVRA Health Care
- Exchange
- STOK Nasdaq
- SVRA Nasdaq
- Market Cap
- STOK 517.0M
- SVRA 528.3M
- IPO Year
- STOK 2019
- SVRA N/A
- Fundamental
- Price
- STOK $11.58
- SVRA $2.06
- Analyst Decision
- STOK Strong Buy
- SVRA Buy
- Analyst Count
- STOK 5
- SVRA 7
- Target Price
- STOK $24.50
- SVRA $7.57
- AVG Volume (30 Days)
- STOK 534.4K
- SVRA 2.5M
- Earning Date
- STOK 08-06-2025
- SVRA 08-11-2025
- Dividend Yield
- STOK N/A
- SVRA N/A
- EPS Growth
- STOK N/A
- SVRA N/A
- EPS
- STOK 0.88
- SVRA N/A
- Revenue
- STOK $190,908,000.00
- SVRA N/A
- Revenue This Year
- STOK $378.84
- SVRA N/A
- Revenue Next Year
- STOK N/A
- SVRA N/A
- P/E Ratio
- STOK $13.21
- SVRA N/A
- Revenue Growth
- STOK 2333.81
- SVRA N/A
- 52 Week Low
- STOK $5.35
- SVRA $1.89
- 52 Week High
- STOK $16.15
- SVRA $5.11
- Technical
- Relative Strength Index (RSI)
- STOK 67.25
- SVRA 34.43
- Support Level
- STOK $11.43
- SVRA $2.13
- Resistance Level
- STOK $12.25
- SVRA $2.49
- Average True Range (ATR)
- STOK 0.51
- SVRA 0.15
- MACD
- STOK 0.02
- SVRA -0.01
- Stochastic Oscillator
- STOK 75.90
- SVRA 8.41
About STOK Stoke Therapeutics Inc.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.
About SVRA Savara Inc.
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.